Alpine Associates Management Inc. purchased a new stake in NxStage Medical, Inc. (NASDAQ:NXTM) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 3,991,458 shares of the medical device company’s stock, valued at approximately $110,163,000. NxStage Medical accounts for about 3.7% of Alpine Associates Management Inc.’s holdings, making the stock its 9th largest position. Alpine Associates Management Inc. owned 6.03% of NxStage Medical as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds also recently modified their holdings of NXTM. Prudential Financial Inc. acquired a new stake in shares of NxStage Medical in the third quarter valued at about $202,000. Amalgamated Bank increased its stake in shares of NxStage Medical by 7.1% in the second quarter. Amalgamated Bank now owns 8,357 shares of the medical device company’s stock valued at $210,000 after buying an additional 553 shares during the period. Koch Industries Inc. acquired a new stake in shares of NxStage Medical in the second quarter valued at about $227,000. Suntrust Banks Inc. increased its stake in shares of NxStage Medical by 2.3% in the second quarter. Suntrust Banks Inc. now owns 9,480 shares of the medical device company’s stock valued at $237,000 after buying an additional 209 shares during the period. Finally, BNP Paribas Arbitrage SA increased its stake in shares of NxStage Medical by 217.0% in the second quarter. BNP Paribas Arbitrage SA now owns 9,676 shares of the medical device company’s stock valued at $243,000 after buying an additional 6,624 shares during the period. 85.68% of the stock is owned by institutional investors.

Several brokerages have recently weighed in on NXTM. Zacks Investment Research raised NxStage Medical from a “hold” rating to a “buy” rating and set a $33.00 price target for the company in a research note on Thursday, August 10th. Craig Hallum cut NxStage Medical from a “buy” rating to a “hold” rating in a research note on Monday, August 7th. BTIG Research cut NxStage Medical from a “buy” rating to a “neutral” rating in a research note on Friday, August 11th. Canaccord Genuity cut NxStage Medical from a “buy” rating to a “hold” rating and set a $30.00 price target for the company. in a research note on Monday, August 7th. Finally, Stephens cut NxStage Medical from an “overweight” rating to an “equal weight” rating and decreased their price target for the company from $33.00 to $30.00 in a research note on Wednesday, August 9th. Two equities research analysts have rated the stock with a sell rating and eight have given a hold rating to the stock. The stock currently has an average rating of “Hold” and a consensus target price of $30.25.

Shares of NxStage Medical, Inc. (NASDAQ:NXTM) opened at $25.35 on Monday. NxStage Medical, Inc. has a 52-week low of $20.45 and a 52-week high of $30.80.

In related news, SVP Matthew W. Towse sold 4,300 shares of the company’s stock in a transaction dated Wednesday, September 20th. The stock was sold at an average price of $27.27, for a total transaction of $117,261.00. Following the sale, the senior vice president now owns 28,721 shares in the company, valued at approximately $783,221.67. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, President Joseph E. Turk, Jr. sold 1,000 shares of the company’s stock in a transaction dated Tuesday, September 5th. The shares were sold at an average price of $27.95, for a total value of $27,950.00. Following the sale, the president now owns 73,903 shares in the company, valued at approximately $2,065,588.85. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 13,300 shares of company stock worth $359,076. 4.70% of the stock is owned by corporate insiders.

COPYRIGHT VIOLATION NOTICE: “Alpine Associates Management Inc. Takes Position in NxStage Medical, Inc. (NXTM)” was posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this article on another website, it was illegally copied and republished in violation of international trademark and copyright laws. The original version of this article can be read at https://www.thecerbatgem.com/2017/12/04/alpine-associates-management-inc-takes-position-in-nxstage-medical-inc-nxtm.html.

NxStage Medical Profile

NxStage Medical, Inc is a medical technology company. The Company develops, manufactures and markets products and services for patients suffering from chronic or acute kidney failure. It operates through three segments. The System One segment includes revenues from the sale and rental of the System One and PureFlow SL dialysate preparation equipment and the sale of disposable products in the home and critical care markets.

Institutional Ownership by Quarter for NxStage Medical (NASDAQ:NXTM)

Receive News & Stock Ratings for NxStage Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NxStage Medical Inc. and related stocks with our FREE daily email newsletter.